Using microarray technique, genome-wide search for genes was undertaken to better identify subsets of patients with diffuse large B-cell lymphoma (DLBCL). This hematologic cancer in adult is heterogeneous in nature and morphologically distinguishable forms of DLBCL do not predict outcome of the disease. Currently used clinical and histopathological criteria to select high-risk patients for intensive treatment are therefore, not accurate. Specific genetic abnormalities determine the aggressiveness of this cancer. The microarray based technique identifies a large number of molecular markers that correlate very well with outcome of the disease and is found to be superior in prognostication of disease outcome. The molecular markers identified are highly informative and are key players in critical steps in tumor development as well as tumor suppression. Microarray technique could be effectively used not only to predict treatment outcome in DLBCL patients but could be used to design rational drugs for intervention.
Go to Previous Page
Go to Next Page